Published 1 month ago • loading... • Updated 1 month ago

CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai

On Feb. 12, 2026, CARsgen Therapeutics Holdings Limited, via its subsidiary CARsgen Diagnostics, signed agreements with Shanghai Jingong Enterprise to build a CAR‑T manufacturing base in Jinshan District, with investment up to RMB370 million.
CARsgen says the move responds to commercialization needs for its marketed zevorcabtagene autoleucel and satricabtagene autoleucel in NDA stage, aligning with national and local biopharmaceutical policy authorities.
Structuring the transaction with a repurchase mechanism reflects the company’s financial planning, requiring no significant early‑stage capital from CARsgen and preserving cash for core R&D and market expansion.
Expanding capacity to international standards aims to support commercialization and competitiveness, and CARsgen says this investment lays the foundation for mass production of CT0596 and CT1190B while creating long‑term value for shareholders.
CARsgen says its end‑to‑end capabilities support expansion, but these forward‑looking plans are subject to Principal Risks and Uncertainties disclosed in its reports.

Insights by Ground AI

38 Articles

LoudounTimes.com

+37 Reposted by 37 other sources

Center

CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in Jinshan, Shanghai

SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that through its indirectly wholly-owned subsidiary CARsgen Diagnostics, it has signed Strategic Cooperation Agreements agreements with Shanghai…

1 month ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year